CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 16 No. 5
 

Androgen Deprivation Therapy Linked to Increased Cardiac Disease Mortality Risk

May 1, 2007

ORLANDO—Androgen deprivation therapy (ADT) for prostate cancer may be associated with increased risk of death from cardiac disease in men aged 65 and older, according to a study presented at the 2007 ASCO Prostate Cancer Symposium (abstract 298). "At 5 years, men 65 and older who were on ADT had a 3% risk of dying from cardiac causes, compared with a 0.9% risk in men who were not on ADT," reported Henry K. Tsai, MD, a resident physician in the Harvard Radiation Oncology Program.

Androgen deprivation therapy is known to elevate body mass index, increase lipids, and induce the onset of diabetes, all of which raise the risk of death from heart disease, Dr. Tsai said. He and his colleagues investigated whether the use and duration of ADT was associated with time to cardiac mortality and all-cause mortality in men treated for prostate cancer by radical prostatectomy, brachytherapy, cryotherapy, and external-beam radiotherapy with and without androgen deprivation.

They reviewed data on 3,636 men treated for localized prostate cancer from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database, a national registry of prostate cancer patients. Of this number, 735 received ADT for 1 to 32.9 months (median duration, 4.1 months), and 2,901 did not receive ADT.

After controlling for age and coronary artery disease risk factors, the duration of ADT (adjusted HR 1.1, P = .01) and age (adjusted HR 1.1, P = .04) were significantly associated with a shorter time to cardiac mortality, Dr. Tsai said. After controlling for pretreatment PSA levels, Gleason score, and tumor category, the duration of ADT was also associated with a shorter time to all-cause mortality. When stratified by age (< 65 years vs > 65 years), the increase in cardiac mortality associated with ADT use remained significant in older men (P = .004) but not in younger men.

"Our results need to be validated in prospective studies in order to prove cause and effect, but they do suggest that we should monitor men who receive ADT more closely for cardiac disease risk," Dr. Tsai concluded.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • A 48-Year-Old Woman With Irregular Vaginal Bleeding
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Soluble HER2 Levels Prognostic Factor in HER2+ Breast Cancer
  • ASCO: PD-L1 Antibody Elicits Durable Response in RCC
  • RECORD-3: Sunitinib Still Standard First-Line Treatment in Metastatic RCC
  • ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients
  • Preventing Burnout in Oncology
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy